Age-dependent effect of metabolic phenotypes on carotid atherosclerotic disease in coronary heart disease patients (CORDIOPREV study)

Francisco M. Gutierrez-Mariscal1,2, Antonio García-Ríos1,2, Purificación Gómez-Luna1,2, Carolina Fernández-Gandara1,2, Magdalena P. Cardelo1,2, Silvia de la Cruz-Ares1,2, Fernando Rodríguez-Cantalejo3, Raul M. Luque2,4, Ana León-Acuña1,2, Javier Delgado-Lista1,2, Pablo Perez-Martinez1,2, Elena M. Yubero-Serrano1,2,† and José Lopez-Miranda1,2,*

Abstract

Background: Aging is associated with a high risk for cardiovascular disease. The relation of obesity and risk of cardiovascular events appears to be more closely linked to certain clinical or metabolic phenotypes than to obesity itself. Our aim was to establish whether aging influenced the metabolic phenotypes regarding to cardiovascular risk, evaluated by changes in the intima media thickness-common carotid (IMT-CC), in coronary heart disease (CHD) patients.

Methods: In this cross-sectional study, 1002 CHD patients were studied at entry from the CORDIOPREV study. We performed carotid ultrasound assessment to obtain their IMT-CC values. Carotid atherosclerosis was considered to exist if IMT-CC > 0.7 mm.

Results: Age determined a higher IMT-CC, regardless metabolic phenotype (all \( p < 0.05 \)). Metabolically healthy non-obese (MHNO) aged< 60 showed a lesser prevalence for carotid atherosclerotic disease than metabolically sick non-obese (MSNO) and obese (MSO), while MHNO aged> 60 only showed less prevalence for the disease than the MSO. Carotid atherosclerosis associated with age, sex, impaired fasting glucose (IFG), hypertension and high sensitivity C-reactive protein (hsCRP). However, in patients aged< 60, it associated with sex and IFG and in the age ≥ 60 group, with hypertension and hsCRP.

(Continued on next page)


**Background**

Aging can be defined as a natural process in which the chances of survival of an organism gradually decline. It is a multifactorial process involving genetic and environmental factors [22, 30]. Aging is associated with an increased risk of suffering age-related diseases such as diabetes, cancer, neurodegenerative diseases or dementia, and is also widely considered as a cardiovascular risk factor [25]. It is common knowledge that body weight tends to increase with age, except in the elderly, while the prevalence of metabolic disease is higher among older individuals, particularly those with obesity [3, 17].

Obesity, defined as abnormal or excessive body fat accumulation, is related to an increased risk of cardiometabolic diseases [21, 31]. Over the past decades, it has increased worldwide as is now considered a pandemic, not only in the middle-aged or pediatric population, but also in the elderly [7, 29]. There is increasing evidence to suggest that not all individuals in obese populations display metabolic disorders and a high cardiovascular risk associated with obesity and, conversely, not all normal-weight individuals are in a favorable metabolic condition [10]. In fact, our current knowledge suggests that it is not obesity itself, but certain clinical or metabolic phenotypes associated with it, which are linked to an increase of the cardiovascular risk [12, 15, 28]. In this context, the so-called metabolically healthy obese phenotype is characterized by increased body fat and a favorable cardiovascular profile (high levels of HDL-cholesterol, normal glucose and triglyceride levels and good insulin sensitivity) [11, 26]. However, normal-weight individuals with metabolic disease show early signs of insulin resistance, hyperinsulinemia, atherogenic dyslipidemia and hypertension, with a high susceptibility to develop diabetes and cardiovascular disease (CVD) [11, 15]. However, to date, it is not known whether the associated cardiovascular risk with metabolic phenotypes could be modified by age.

Taking all the above into account, the aim of the present study was to establish whether age influences the cardiovascular risk associated with metabolic phenotypes (the presence/or absence of obesity and/or metabolic disease), measured by intima-media thickness of both the common carotid arteries (IMT-CC), as marker of carotid atherosclerosis, in a large cohort of coronary heart disease (CHD) patients. The identification of these potential associations would provide evidence to allow the use of more intensive medical interventions and prevention strategies aimed at reducing CVD risk and delay an age-related decline in health.

**Methods**

**Population**

This work has been carried out in the setting of the CORDIOPREV study (Clinical Trials Registry NCT00924937). The study protocol was designed in accordance with the principles of the Declaration of Helsinki, approved by the Human Investigation Review Committee of the Reina Sofia University Hospital, and according to institutional and Good Clinical Practice guidelines. The CORDIOPREV study is described in depth in previously published report [6]. For the specific aim of this work, we performed a cross-sectional analysis of the CORDIOPREV population at baseline and the patients were classified according to: 1) Age, up and under the median of our studied population, 60 years; 2) the presence/or absence of obesity [body mass index (BMI) < 30 and ≥ 30 and 3) metabolic disease (described below). From the initial sample of 1002 subjects, we included only 939 subjects: those whose carotid ultrasound, analytical and anthropometric data were available. The reasons for the lack of data for the remaining 63 patients were as follows: 37 refused to undergo the echography, 14 withdrew from the study before conducting the test and 12 for other reasons [28].

**Metabolic phenotypes**

The different metabolic phenotypes included in the study were defined as follows: 1. Metabolically healthy non-obese (MHNO): BMI < 30 and < 2 factors of cardiometabolic criteria. 2. Metabolically healthy obese (MHO): BMI ≥ 30 and < 2 factors of cardiometabolic criteria. 3. Metabolically sick non-obese (MSNO): BMI < 30 and ≥ 2 factors of cardiometabolic criteria. 4. Metabolically sick obese (MSO): BMI ≥ 30 and ≥ 2 factors of cardiometabolic criteria. Description of cardiometabolic disease criteria are in supplemental material.
Laboratory tests
At 8.00 am, following a 12-h fast, the patients were admitted to the laboratory for anthropometric and biochemical tests [BMI, waist circumference, Waist to Height Ratio (WHTR), systolic blood pressure (SBP), diastolic blood pressure (DBP), HDL-cholesterol, LDL-cholesterol, triglycerides, cholesterol, high sensitive C-reactive protein (hsCRP), glucose, hemoglobin A1c (HbA1c) and homeostatic model assessment for insulin resistance (HOMA-IR)] as described in supplemental material.

Intima media thickness assessment
All the patients were examined in supine position with the neck hyper-extended and the chin turned to one side. The carotid arteries were examined bilaterally using a Doppler ultrasound high-resolution B-mode (Envisor C Ultrasound System, Phillips, USA), following the recommendations of the American Society of Echocardiography Carotid Intima-Media Thickness Task Force [27]. The observers were unaware of the patients’ demographic and cardiovascular risk data during the assessment. The measurements were taken using semi-automatic software (QLAB Advance Ultrasound Quantification Software, v5.0, Phillips, USA). Three measurements were taken for each patient, and we obtained the general mean IMT-CC. Carotid atherosclerotic disease was defined by IMT-CC ≥ 0.7 mm [18, 23]. This cutoff value was used to calculate the prevalence of carotid atherosclerotic disease as a percentage of the patients with IMT-CC ≥ 0.7 mm from the total number of patients in each group analyzed.

Statistical analysis
The statistical analyses were carried out using SPSS version 19.0 for Windows (SPSS Inc., Chicago, IL, USA). Continuous data were compared by analysis of variance (ANOVA) in which smoking habit and sex were included as covariates. Categorical variables were compared using Chi Square tests. In order to assess the association between the phenotypes and the presence of carotid atherosclerotic disease, an odds ratios (OR) analysis was performed. Furthermore, backward multiple linear and logistic analysis were carried out to estimate the association between cardiovascular risk factors and IMT-CC values. The differences were considered significant when p < 0.05. All the data presented in figures and tables are expressed as means ± standard error (SE).

Results
Study population characteristics based on age and metabolic phenotypes
In the analysis of the influence of age and metabolic phenotypes on biochemical and anthropometrics characteristics of the population (Shown in Supplemental Table 1), waist circumference and cholesterol showed a differential effect (p < 0.05): MSO patients aged < 60 years showed the highest waist circumference and MSNO and MSO patients aged ≥ 60 years exhibited the lowest cholesterol. Furthermore, MSO patients aged ≥ 60 years had higher insulin and HbA1c levels, but fewer BMI compared to those aged < 60 years (p < 0.05); MHO patients aged ≥ 60 years showed higher HDL-cholesterol levels compared to those aged < 60 years (p < 0.05). In both age groups, MSO patients showed higher BMI, HOMA-IR, HbA1c and hsCRP levels compared to the rest of metabolic phenotypes (all p < 0.05). However, only MSO patients aged ≤ 60 years showed higher waist circumference, glucose and insulin levels, and lower HDL-cholesterol levels, compared to the rest of metabolic phenotypes (all p < 0.05). In the analysis of WHTR, a biomarker of fat visceral deposit, age > 60 years determined higher value than age < 60 years, being all of them equal or upper 0.6 points which shows high risk of fat visceral localization with a subsequent loss in metabolic flexibility. In each group of age, we observed that in those age > 60 years obesity determined higher WHTR than non-obese, however in age < 60 years the highest value for this parameter belongs to those MSO.

Differences in IMT-CC between metabolic phenotypes are influenced by age
Regarding to the influence of metabolic phenotypes on IMT-CC, age resulted in a higher IMT-CC regardless of the metabolic phenotype (all p < 0.05) (Fig. 1). In the group of patients aged < 60 years, MHNO had the lowest IMT-CC compared to the other phenotypes (p < 0.05). In the group of patients aged ≥ 60 years, MHNO showed the lowest IMT-CC, while MSO patients presented the highest IMT-CC (p < 0.05), with intermediate values for IMT-CC in MHO and MSNO patients (Fig. 1).

Age produces differences in the prevalence of carotid atherosclerotic disease according to metabolic phenotypes
In order to find a link between the different metabolic phenotypes and the presence or not of carotid atherosclerotic disease, defined as IMT-CC ≥ 0.7 mm, we calculated OR for both the whole study population and according to age. Table 1 shows the prevalence of carotid atherosclerotic disease and OR values. When we evaluated the whole population, the MHNO patients presented the lowest prevalence of carotid atherosclerotic disease compared to the rest of phenotypes. In patients aged < 60 years, MHNO showed less prevalence of carotid atherosclerosis than MSNO and MSO phenotypes, but not MHO. However, in patients aged ≥ 60 years, MHNO showed less prevalence of carotid...
atherosclerosis than MSO, but not less than the other phenotypes (Table 1).

Regarding to the OR analysis, we observed that in the whole population, MHO, MSNO and MSO phenotypes were associated with the presence of carotid atherosclerosis, taking the MHNO phenotype as a reference. In patients aged< 60 years, the MHO phenotype was not associated with a higher prevalence of the disease compared to MHNO (OR < 1), but this association did appear with the presence of metabolic disease (OR = 2.42 for MSNO and 2.85 for MSO), although the value of prevalence of carotid atherosclerosis disease was seen to increase from MHNO to MSO. However, in the group of patients aged≥ 60 years, MHO and MSNO did not result in a higher probability of the disease than MHNO, while MSO showed an association with the presence of the disease [OR: 1.87 (1.02–3.42)].

Multiple regression analysis
In order to study which biochemical and anthropometric parameters are involved in carotid atherosclerotic disease, we performed a multiple regression analysis. The results showed that age, BMI, HDL cholesterol, and systolic blood pressure were independently associated with the presence of carotid atherosclerosis.

Table 1 Prevalence of carotid atherosclerosis diseases according to metabolic phenotypes and its association study by Odds Ratios

|                      | MHNO | MHO | MSNO | MSO | χ² Test |
|----------------------|------|-----|------|-----|---------|
| All population (n = 939) | 109  | 71  | 305  | 454 | p = 0.003 |
| Carotid Atherosclerosis disease prevalence (IMT-CC ≥ 0.7 mm) | 33.9%<sup>a</sup> | 49.3%<sup>b</sup> | 49.2%<sup>b</sup> | 54.0%<sup>b</sup> |  |
| Odds Ratio           | 1.89 (1.03–3.49) | 1.88 (1.19–2.97) | 2.28 (1.47–3.53) | |
| Age < 60 (n = 435)   | 58   | 26  | 141  | 210 | p = 0.028 |
| Carotid Atherosclerosis disease prevalence (IMT-CC ≥ 0.7 mm) | 19.0%<sup>a</sup> | 30.8%<sup>a,b</sup> | 36.2%<sup>b</sup> | 40.0%<sup>b</sup> | |
| Odds Ratio           | 1.90 (0.66–5.48) | 2.42 (1.15–5.08) | 2.85 (1.40–5.81) | |
| Age ≥ 60 (n = 504)   | 51   | 45  | 164  | 244 | p = 0.209 |
| Carotid Atherosclerosis disease prevalence (IMT-CC ≥ 0.7 mm) | 51.0%<sup>a</sup> | 60.0%<sup>a,b</sup> | 60.4%<sup>a,b</sup> | 66.0%<sup>b</sup> | |
| Odds Ratio           | 1.44 (0.64–3.24) | 1.46 (0.78–2.75) | 1.87 (1.02–3.42) | |

Carotid Atherosclerosis disease (carotid intima media thickness ≥ 0.7 mm) prevalence is expressed in percentage. Odds ratio values are calculated using MHNO phenotype as reference (95% confidence interval). Odds Ratio in bold mean that all values in the confidence interval are higher than 1. χ² Test performed to compare prevalence of carotid atherosclerosis disease between metabolic phenotypes. Percentages in a row with superscripts with different letters a and b mean differences between phenotype group.
disease among the different metabolic phenotypes, we performed a multiple logistic regression analysis (Table 2). In this regard, the presence of carotid atherosclerosis in the whole population seems to be associated with age, sex, IFG, hypertension and hsCRP. However, when we looked for these associations in each group split by age, we observed that in patients aged<60 years, carotid atherosclerosis was associated with sex and IFG, while in patients aged≥60 years, it appeared to be associated with hypertension and hsCRP.

**Discussion**

This study provides new findings about risk factors for carotid atherosclerosis associated with metabolic status and obesity, defined by metabolic phenotypes, and its relationship with age in patients with CHD. Our data highlights the age-dependency of this association and suggests that the relative importance of metabolic parameters and obesity differ in patients below and over 60 years old. Therefore, in patients aged<60 years, there is an increased risk of carotid atherosclerosis among the MSO, MSNO and MHO groups compared to MHNO, where IFG seems to be the most influential metabolic parameter. However, in patients aged≥60 years, those classified as MSO showed the highest risk for the disease, being hypertension, hsCRP and WHTR (a biomarker of fat visceral deposit) [24] the metabolic parameters that more contributed to the risk for carotid atherosclerosis. In the study of predictive and earlier biomarkers for CVD, IMT-CC is considered a surrogate marker that allows the anatomical changes in the arterial wall to be explored and quantified [14, 16] and can be used as an indicator of the presence of carotid atherosclerosis [5, 13]. Among risk factors studied regarding the development of carotid atherosclerotic disease, weight is considered an independent risk factor for CVD and is associated with diabetes, hypertension and dyslipidemia, as well as other lifestyle risk factors such as physical inactivity and poor diet [20]. In this area, Choi et al. found that older MSNO adults showed a markedly higher risk of all-cause mortality, whereas overweight or obese subjects without metabolic disease had a comparatively lower risk of death [4].

The MHO phenotype has been described as an intermediate stage between a healthy and sick status, producing the same risk of suffering a cardiovascular event as MHNO [2]. Although this has been noted in most published studies, in the present study we observed a higher association with carotid atherosclerosis for the MHO phenotype than for MHNO. However, when we analyzed patients according to age, MHO patients aged< 60 years showed no link to a higher prevalence of carotid

### Table 2 Multiple logistic regression

| Variables          | Coefficients | SE   | p     | Odds Ratio | 95% CI        |
|--------------------|--------------|------|-------|------------|---------------|
| **The whole population** |              |      |       |            |               |
| Age                | 1.118        | 0.157| 0.000 | 3.059      | 2.248–4.162   |
| Sex                | 0.868        | 0.219| 0.000 | 2.382      | 1.550–3.662   |
| IFG                | 0.455        | 0.155| 0.003 | 1.577      | 1.163–2.138   |
| hsCRP              | 0.303        | 0.166| 0.067 | 1.359      | 0.979–1.874   |
| Hypertension       | 0.477        | 0.163| 0.003 | 1.611      | 1.170–2.188   |
| WHTR               | 1.897        | 1.135| 0.095 | 6.666      | 0.720–61.672  |
| **Patients Age < 60 years** |          |      |       |            |               |
| Sex                | 0.849        | 0.414| 0.041 | 2.337      | 1.037–5.264   |
| IFG                | 0.836        | 0.228| 0.000 | 2.308      | 1.478–3.605   |
| **Patients Age ≥ 60 years** |          |      |       |            |               |
| Sex                | 0.880        | 0.263| 0.001 | 2.411      | 1.440–4.038   |
| Hypertension       | 0.831        | 0.225| 0.000 | 2.295      | 1.476–3.571   |
| hsCRP              | 0.478        | 0.231| 0.039 | 1.612      | 1.024–2.537   |
| WHTR               | 2.830        | 1.526| 0.064 | 16.940     | 0.850–337.420 |

R² = 0.167, constant = −3.251 (p = 0.000). Alcohol consumption, smoking, LowHDL-c, HOMA-IR, Obesity and Waist Circumference have been eliminated from the model (p > 0.05)

R² = 0.072, constant = −1.859 (p = 0.000). Alcohol consumption, smoking, Obesity, LowHDL-c, HOMA-IR, HyperTG, Waist Circumference, Hypertension and hsCRP have been eliminated from the model (p > 0.05)

R² = 0.099, constant = −2.785 (p = 0.008). Alcohol consumption, smoking, Obesity, LowHDL-c, HOMA-IR, HyperTG, IFG and Waist Circumference have been eliminated from the model (p > 0.05)

Multiple Logistic Regression with Age, Sex, IFG, LowHDL-c, hsCRP, HOMA-IR, Hypertension, Obesity, Waist Circumference, WHTR Waist to Height Ratio, HyperTG Alcohol consumption and Smoking as variable proved in the model. IFG Impaired Fasting Glucose, hsCRP high sensitive C-reactive protein, HOMA-IR homeostatic model assessment for insulin resistance, HyperTG Hypertrigliceridemia
atherosclerosis. Moreover, the MSNO and MSO phenotypes showed a higher prevalence than MHNO. Indeed, an increasing prevalence of carotid atherosclerosis can be seen between MHNO and MSO.

Recent data from a 20-year follow up suggest that cumulative incidence rates for CHD, stroke and survival probability in individuals with suboptimal health (≤two metabolic diseases factors) were intermediate between the healthy and unhealthy subgroups, which was not affected by the BMI [8]. In contrast to our results, an increasing prevalence of carotid atherosclerosis can be seen between MHNO and MSO.

Recent data from a 20-year follow up suggest that cumulative incidence rates for CHD, stroke and survival probability in individuals with suboptimal health (≤two metabolic diseases factors) were intermediate between the healthy and unhealthy subgroups, which was not affected by the BMI [8]. In contrast to our results, an increasing prevalence of carotid atherosclerosis can be seen between MHNO and MSO. Indeed, an increasing prevalence of carotid atherosclerosis can be seen between MHNO and MSO.

Recent data from a 20-year follow up suggest that cumulative incidence rates for CHD, stroke and survival probability in individuals with suboptimal health (≤two metabolic diseases factors) were intermediate between the healthy and unhealthy subgroups, which was not affected by the BMI [8]. In contrast to our results, an increasing prevalence of carotid atherosclerosis can be seen between MHNO and MSO.

Conclusion
In conclusion, our results suggest that in CHD patients, there is an age-dependent effect of metabolic phenotypes on carotid atherosclerotic disease. CHD patients aged≥60 years lose their metabolic flexibility compared to patients aged< 60 years. This fact indicates the need to focus on therapeutic strategies in order to modify those parameters related to obesity and metabolic inflexibility in patients with CHD before entering old age.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12877-020-01544-5.

Additional file 1.

Abbreviations
ANOVA: Analysis of Variance; BMI: Body Mass Index; CHD: Coronary Heart Disease; CVD: Cardiovascular Disease; DBP: Diastolic Blood Pressure; HbA1c: Hemoglobin A1c; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; hsCRP: High sensitivity C-Reactive Protein; IFG: Impaired Fasting Glucose; IMT-CC: Intima Media Thickness-Common Carotid; MHO: Metabolically Healthy non-Obese; MSNO: Metabolically Sick non-Obese; MSO: Metabolically Sick Obese; O: Odds Ratio; SBP: Systolic Blood Pressure; SE: Standard Error; WHTR: Waist to Height Ratio
Acknowledgments
We would like to thank the EASP (Escuela Andaluza de Salud Publica), Granada (Spain), for carrying out the randomization process in this study. The CIBEROBN is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.

Authors’ contributions
FMG-M, EMY-S, and JL-M designed the study hypothesis, analyzed the data, and wrote the manuscript; EMY-S and JL-M had primary responsibility for the final content of the manuscript; JD-L, PP-M, AL-A and RML contributed to the editing of the manuscript; FMG-M, AG-R, PG-L, CF-G, MFC, SM-CA and FR-C conducted the research; AL-A and JD-L provided the statistical review; PP-M and RW-L contributed to the interpretation of data and substantively revised the manuscript; JL-M and EMY-S designed the research and supervised the study, and all authors read and approved the final manuscript.

None of the authors reported a conflict of interest related to the study.

Funding
The CORDIOPREV study is supported by the Fundacion Patrimonio Comunal Olivarero, Junta de Andalucía (Consejería de Salud, Consejería de Agricultura y Pesca, Consejería de Innovación, Ciencia y Empresa), Diputaciones de Jaén y Córdoba, Centro de Excelencia en Investigación sobre Aceite de Oliva y Salud and Ministerio de Medio Ambiente, Medio Rural y Marino, Gobierno de España. The CORDIOPREV study also received research grants from Consejería de Salud, Junta de Andalucía (PI19/3/09 to Dr. Lopez-Miranda, PI-0252/09 to Dr. Delgado-Lista, and PI-0058/10 to Dr. Perez-Martinez); Proyecto de Excelencia, Consejería de Economía, Innovación y Empleo (CVI-7450 to Dr. Lopez-Miranda); and from the Ministerio de Economía y Competitividad (AGL2012–39615 and AGL2015–67969P) to Dr. Lopez-Miranda integrated into the framework of the National Plan for Scientific Research Technological Development and Innovation 2008–2011 and 2013–2016, co-financed by the Instituto de Salud Carlos III (ISCIII) of Spain and also by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund (FEDER). It was also partly supported by a Research Grant from the European Community (NUTRITECH European Integrated Project-289511). Dr. Gutiérrez Mariscal is supported by a research grant from the European Community (NUTRITECH European Regional Development Fund (FEDER). It was also partly supported by the Instituto de Salud Carlos III (ISCIII) of Spain and also by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund (FEDER).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was designed in accordance with the principles of the Declaration of Helsinki, approved by the Human Investigation Review Committee of the Reina Sofia University Hospital, and according to institutional and Good Clinical Practice guidelines. The participant informed consent was submitted to the Ethics Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 7 October 2019 Accepted: 1 April 2020
Published online: 22 April 2020

References
1. Aparicio HI, et al. Overweight, obesity, and survival after stroke in the Framingham heart study. J Am Heart Assoc. 2017;6:e004271.
2. Amlot J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men Diabetes care. Diabetes Care. 2011;34:61–5.
3. Bradshaw PT, Monda KL, Stevens J. Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the atherosclerosis risk in communities study. Obesity (Silver Spring). 2013;21:203–9.
4. Choi KM, et al. Higher mortality in metabolically obese normal-weight people than in metabolically obese healthy subjects in elderly Koreans. Clin Endocrinol. 2013;79:364–70.
5. Coll B, Betriu A, Feinleib SB, Valdivielso JM, Zamorano JL, Fernandez E. The role of carotid ultrasound in assessing carotid atherosclerosis in individuals at low-to-intermediate cardiovascular risk. Rev Esp Cardiol (Engl Ed). 2013;66:929–34. https://doi.org/10.1016/j.rec.2013.05.030.
6. Delgado-Lista J, et al. Coronary Diet Intervention with Olive oil and Cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat diet on cardiovascular disease in coronary patients. Am Heart J. 2016;177:42–50. https://doi.org/10.1016/j.amheath.2016.04.011.
7. Flegal KM, Kruznosen-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–91. https://doi.org/10.1001/jama.2016.458.
8. Guo F, Garvey WT. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: stability of metabolic health status in adults. Obesity (Silver Spring). 2016;24:516–25.
9. Hanner M, Bell JA, Sabia S, Batty GD, Kivimäki M. Stability of metabolically healthy obesity over 8 years: the English longitudinal study of ageing. Eur J Endocrinol. 2015;173:703–8.
10. Karelis AD. To be obese—does it matter if you are metabolically healthy? Nat Rev Endocrinol. 2011;7:699–700. https://doi.org/10.1038/nrendo.2011.181.
11. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, Rabasa-Lhoret R. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50. https://doi.org/10.1210/jc.2005-0482.
12. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569–75. https://doi.org/10.1210/jc.2004-0165.
13. Kim HN, Kim SH, Eun YM, Song SW. Obesity with metabolic abnormality is associated with the presence of carotid atherosclerosis in Korean men: a cross-sectional study. Diabetol Metabol Syndrome. 2015;7:68.
14. Kim HS, Cho KI. Association of carotid artery parameters of atherosclerosis in coronary artery disease. J Cardiovasc Ultrasound. 2013;21:72–80. https://doi.org/10.4250/jcu.2013.21.2.72.
15. Lopez-Miranda J, Perez-Martinez P. It is time to define metabolically obese but normal-weight (MONW) individuals. Clin Endocrinol (Oxf). 2013;79:314–5. https://doi.org/10.1111/cen.12181.
16. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459–67. https://doi.org/10.1161/CIRCULATIONAHA.106.628875.
17. Markedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag health study), Norway. J Am Coll Cardiol. 2016;67:1071–8.
18. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J. 2010;31:1682–9. https://doi.org/10.1093/eurheartj/ehq185.
19. Perez-Martinez P, et al. Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis. J E Clin Investig. 2014;4:1053–64. https://doi.org/10.1011/ei.12389.
20. Perez-Martinez P, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutr Rev. 2017;75:307–26. https://doi.org/10.1093/nutrit/nux014.
21. Pischon T, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:2105–20. https://doi.org/10.1056/NEJMoa0801891.

22. Rescigno T, Micocucci L, Tecce MF, Capasso A. Bioactive nutrients and nutrigenomics in age-related diseases. Molecules. 2017;22:E105. https://doi.org/10.3390/molecules22010105.

23. Rohde LE, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:1765–70.

24. Shen SW, et al. Waist-to-height ratio is an effective indicator for comprehensive cardiovascular health. Sci Rep. 2017;7:1–7. https://doi.org/10.1038/srep43046.

25. Sniderman AD, Furbeg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet. 2008;371:1547–9.

26. Song Y, Manson JE, Meigs JB, Ridker PM, Buring JE, Liu S. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol. 2007;100:1654–8. https://doi.org/10.1016/j.amjcard.2007.06.073.

27. Stein JH, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography carotid intima-media thickness task force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93–111; quiz 189-190. https://doi.org/10.1016/j.echo.2007.11.011.

28. Talavera-Garcia E, et al. Influence of obesity and metabolic disease on carotid atherosclerosis in patients with coronary artery disease (CordioPrev study). PLoS one. 2016;11:e0153006. https://doi.org/10.1371/journal.pone.0153006.

29. Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open. 2014;2:E18–26. https://doi.org/10.9778/cmaoj.20130016.

30. Weinert BT, Timiras PS. Invited review: theories of aging. J Appl Physiol. 2003;95:1706–16. https://doi.org/10.1152/japplphysiol.00288.2003.

31. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008;117:1658–67. https://doi.org/10.1161/CIRCULATIONAHA.107.739714.